Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Content 3 Undervalued Names Too Cheap to IgnoreWritten by Nathan Reiff. Publication Date: 3/7/2026. 
At a Glance - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
Highly publicized growth trajectories of some of the biggest companies out there may make it seem like 2026 is not a prime time for a value strategy. Still, several sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth. The companies below represent potential value plays, based on historically low value metrics or competitive measures relative to peers and the broader market. They also offer added benefits, such as compelling dividends or promising new product developments. While pure value opportunities can be harder to find when many high-potential companies are back in investor favor — and some apparent bargains have deteriorating fundamentals or other red flags — well-established, stable names can still be attractive value prospects. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works Med-X is gearing up for a possible Nasdaq listing (ticker: MXRX). But the real opportunity is now – before they hit the big stage.
Their all-natural pesticides have outperformed chemical brands in independent lab tests, providing safer solutions without sacrificing results.
With $6.4M in sales in just four years, they're getting ready for the next step. Become a Med-X Shareholder Before Their Nasdaq Plans Unfold Although shares have climbed more than 28% in the past year, bringing its market capitalization to nearly $300 billion, biopharma giant Merck & Co. Inc. (NYSE: MRK) still trades at a price-to-earnings (P/E) ratio of 16.45 — well below the medical industry average of roughly 27. Analysts expect continued growth: the company is projected to see earnings rise by nearly 10% in the coming year and has a 5% additional upside in the near term. Driving Merck's momentum is its pembrolizumab cancer drug, Keytruda, which won approval for subcutaneous injection from the European Commission in late 2025 and generated about $8.4 billion in sales in Q4 2025 — an increase of almost 7% year over year. Keytruda also shows early promise in ovarian cancer, which could expand its addressable patient base. Those factors should help Merck build revenue as it prepares for Keytruda's patent expiration in 2028. Merck's broader drug portfolio is also expanding. The company recently announced phase 3 trial results for clesrovimab-cfor (branded Enflonsia), a treatment for RSV in young children. At the same time, Merck is reorganizing its human health business into two units to make it easier to grow non–cancer-drug sales ahead of Keytruda's patent loss. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors Campbell's (NASDAQ: CPB) shares have fallen about 37% over the past year after the food-and-beverage staple contended with tariffs and inflation. In Q1 fiscal 2026, which ended Nov. 2, 2025, the company reported modest year-over-year declines in organic net sales and consumption, and adjusted earnings per share (EPS) fell 13% year over year. The firm has not yet seen significant margin improvement following its cost-saving initiatives. The near term is likely to remain challenging for the iconic brand, as fiscal-year guidance looks weak overall. That said, improvements in its supply chain and strong brand loyalty — especially for premium offerings — should provide some protection. Evolving tariff dynamics may also ease pressure on the business over time. Campbell's remains a notable dividend play, offering a yield of 5.9%, although its payout ratio is fairly high at more than 80%. Its P/E ratio of 13.5 is the lowest in about four years, which may persuade some investors that the stock is worth considering despite Wall Street caution. US Foods' Recent Rally May Continue; Bottom-Line Growth Remains in Place Foodservice distribution leader US Foods (NYSE: USFD) has seen an almost opposite share-price trend to Campbell's — shares climbed roughly 33% over the last year. Even with that rally, its P/E ratio of 31.6 is reasonable compared with many high-growth names. On the fundamentals, US Foods is making meaningful progress: the company reported improving profitability in the latest quarter and full-year adjusted EBITDA gains of 11% year over year. Better inventory management and cost-of-goods improvements are helping the firm gain traction. With a $4 billion capital deployment plan, US Foods is positioned to sustain revenue growth and continue expanding adjusted EBITDA. Analysts rate USFD shares a Moderate Buy based on 11 Buys and 2 Holds, with roughly 15% upside potential.
| 
